| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 30 December 2024 |
| for |
| Replay Biotechnology UK Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 30 December 2024 |
| for |
| Replay Biotechnology UK Limited |
| Replay Biotechnology UK Limited (Registered number: 13625955) |
| Contents of the Financial Statements |
| for the Year Ended 30 December 2024 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 3 |
| Replay Biotechnology UK Limited |
| Company Information |
| for the Year Ended 30 December 2024 |
| DIRECTOR: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| ACCOUNTANTS: |
| Chartered Accountants |
| TOR |
| Saint-Cloud Way |
| Maidenhead |
| Berkshire |
| SL6 8BN |
| Replay Biotechnology UK Limited (Registered number: 13625955) |
| Balance Sheet |
| 30 December 2024 |
| 30.12.24 | 30.12.23 |
| Notes | £ | £ |
| CURRENT ASSETS |
| Debtors | 4 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 5 | ( |
) | ( |
) |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CAPITAL AND RESERVES |
| Called up share capital |
| Retained earnings |
| SHAREHOLDERS' FUNDS |
| The director acknowledges his responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| The financial statements were approved by the director and authorised for issue on |
| Replay Biotechnology UK Limited (Registered number: 13625955) |
| Notes to the Financial Statements |
| for the Year Ended 30 December 2024 |
| 1. | STATUTORY INFORMATION |
| Replay Biotechnology UK Limited is a |
| The presentation currency of the financial statements is the Pound Sterling (£). |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| The Director intends to wind up Replay Biotechnology UK Limited and as a result the accounts have been prepared on the basis that the Company will cease trading and be wound up in due course. |
| Significant judgements and estimates |
| In the application of the company's accounting policies the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. |
| Actual results may differ from these estimates. |
| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. |
| The company does not make significant estimates and assumptions concerning the future. |
| Turnover |
| The turnover shown in the statement of comprehensive income represents amounts receivable from the ultimate parent undertaking during the period, for the provision of consultancy support functions exclusive of Value Added Tax. |
| Turnover in respect of services provided to the ultimate parent company is calculated as attributable costs plus a mark up in accordance with a cost plus agreement between Replay Holdings Inc, Replay Management Inc |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| Replay Biotechnology UK Limited (Registered number: 13625955) |
| Notes to the Financial Statements - continued |
| for the Year Ended 30 December 2024 |
| 4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 30.12.24 | 30.12.23 |
| £ | £ |
| Amounts owed by group undertakings |
| Other debtors |
| 5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 30.12.24 | 30.12.23 |
| £ | £ |
| Trade creditors |
| Amounts owed to group undertakings |
| Taxation and social security |
| Other creditors |
| 6. | RELATED PARTY DISCLOSURES |
| Replay Holdings Incorporated |
| A company of which Replay is a 100% owned subsidiary |
| 30.12.24 | 30.12.23 |
| £ | £ |
| Amount due from/(to) related party at the balance sheet date | 57,702 | (385,836 | ) |
| Replay Management Incorporated |
| A company which was a 100% subsidiary of Replay Holdings Inc. |
| The company was dissolved on 30 June 2024. |
| 30.12.24 | 30.12.23 |
| £ | £ |
| Amount due from related party at the balance sheet date | - | 461,509 |